BTF granted US patent for 'Bioballs'
By Renate Krelle
Thursday, 23 September, 2004
Thursday, 23 September, 2004
Private Sydney-based biotech BTF has been granted a US patent for its BioBall quality-control product.
The patent protects its BioBall technology, which uses a flow cytometer to count out precisely 30 viable bacteria. The bacteria are freeze dried in a drop of nutrient fluid as a 'Bioball' pellet.
The pellets can be reconstituted and used as a control, eliminating the need for labs to perform routine serial dilutions.
Related News
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
